Viridian Therapeutics
VRDN
27 hedge funds and large institutions have $5.04M invested in Viridian Therapeutics in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
17% more funds holding
Funds holding: 23 → 27 (+4)
17% more capital invested
Capital invested by funds: $4.3M → $5.04M (+$747K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.43% less ownership
Funds ownership: 1.85% → 1.42% (-0.43%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$776K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$744K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$577K |
| 4 |
Renaissance Technologies
New York
|
+$109K |
| 5 |
Squarepoint
New York
|
+$52.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$139K |
| 2 |
Millennium Management
New York
|
-$129K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$48K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
-$42K |
| 5 |
GPFA
Game Plan Financial Advisors
Westlake,
Ohio
|
-$10.9K |
VRDN Hedge Fund Activity: Q1 2020 in Review
27 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2020, worth a combined $5.04M — up 17% from $4.3M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new VRDN positions and 6 closed out — a net gain of 5 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $776K. The largest seller was 683 Capital Management, exiting entirely with an estimated $139K sold.
- 27 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2020, up from 23 in Q4 2019.
- Funds reported $5.04M of Viridian Therapeutics stock for Q1 2020, up 17% quarter-over-quarter.
- 11 funds opened new Viridian Therapeutics positions in Q1 2020 and 6 closed out, a net change of +5 holders.
- The largest Viridian Therapeutics buyer in Q1 2020 was Fidelity Investments, an estimated $776K added.
- The largest Viridian Therapeutics seller in Q1 2020 was 683 Capital Management, an estimated $139K sold.
Based on aggregated 13F filings for Q1 2020.